With the discussions regarding the massive potential for Zantrene to have success in multiple different pillars, as well as the Growth in the market and the expected sales it would generate;
I am interested to hear peoples opinions (preferably backed up with facts), as to which would be better for RAC shareholders in the Short, Medium and Long term.
A) A Partnership with big Pharma
B) A Buyout offer from big Pharma
Buyout or Partnership- Which is better for Shareholders
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.000(0.00%) |
Mkt cap ! $254.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 323 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 2999 | 1 |
View Market Depth
| Last trade - 07.43am 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.56 |
Change
0.000 ( 2.98 %) |
||||
| Open | High | Low | Volume | ||
| $1.53 | $1.56 | $1.53 | 194 | ||
| Last updated 10.20am 22/05/2024 ? | |||||
| RAC (ASX) Chart |
Day chart unavailable